Detection and management of latent tuberculosis in liver transplant patients

Liver Transplantation

Volumn 17, Issue 3, 2011, Pages 306-314

  Jafri, Syed Mohammed ^a   Singal, Amit G ^a   Kaul, Daniel ^a   Fontana, Robert John ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ISONIAZID; PYRIDOXINE; TUBERCULIN;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; FEMALE; FREQUENCY ANALYSIS; GRAFT RECIPIENT; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS C; HUMAN; LATENT TUBERCULOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MILITARY SERVICE; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SKIN TEST; SURVIVAL;

ANTITUBERCULAR AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON-GAMMA; ISONIAZID; KAPLAN-MEIER ESTIMATE; LATENT TUBERCULOSIS; LIVER TRANSPLANTATION; LYMPHOCYTES; MALE; MICHIGAN; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST;

EID: 79952430844     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22203     Document Type: Article

References (43)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC., Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 282: 677-686.
2. Subramanian A, Dorman S, and the AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 (suppl 4): S57-S62.
3. Benito N, Sued O, Moreno A, Horcajada JP, González J, Navasa M, Rimola A., Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74: 1381-1386. (Pubitemid 35379541)
4. Pai M, Zwerling A, Menzies D., Systematic review: T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 174-178.
5. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K., Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
6. Menzies D, Pai M, Comstock G., Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354. (Pubitemid 351650594)
7. Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection to liver transplantation. Am J Transplant 2007; 7: 2797-2801. (Pubitemid 350045785)
8. Johnson PD, Stuart RL, Grayson ML, Olden D, Clancy A, Ravn P, et al. Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 1999; 6: 934-937. (Pubitemid 29529991)
9. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 2005; 12: 1311-1316. (Pubitemid 41626601)
10. Cummings KJ, Smith TS, Shogren ES, Khakoo R, Nanda S, Bunner L, et al. Prospective comparison of tuberculin skin test and QuantiFERON-TB Gold In-Tube assay for the detection of latent tuberculosis infection among healthcare workers in a low-incidence setting. Infect Control Hosp Epidemiol 2009; 30: 1123-1126.
11. Lindemann M, Dioury Y, Beckebaum S, Cicinnati VR, Gerken G, Broelsch CE, et al. Diagnosis of latent tuberculosis infection in patients awaiting liver transplantation. Hum Immunol 2009; 70: 24-28.
12. Hauck FR, Neese BH, Panchal AS, El-Amin W., Identification and management of latent tuberculosis infection. Am Fam Physician 2009; 79: 879-886.
13. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep 1995; 44: 19-34.
14. Codeluppi M, Cocchi S, Guaraldi G, Di Benedetto F, De Ruvo N, Meacci M, et al. Posttransplant Mycobacterium tuberculosis disease following liver transplantation and the need for cautious evaluation of Quantiferon TB Gold results in the transplant setting: a case report. Transplant Proc 2006; 38: 1083-1085. (Pubitemid 43815873)
15. Rao VK, Iademarco EP, Fraser VJ, Kollef MH., The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 1998; 114: 1244-1252. (Pubitemid 28527393)
16. Singh N, Paterson DL., Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27: 1266-1277. (Pubitemid 29242482)
17. Hsu M-S, Wang J-L, Ko W-J, Lee P-H, Chou N-K, Wang S-S, et al. Clinical features and outcome of tuberculosis in solid organ transplant recipients. Am J Med Sci 2007; 334: 106-110. (Pubitemid 47262917)
18. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ., Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009; 15: 894-906.
19. Cavusoglu C, Cicek-Saydam C, Karasu Z, Karaca Y, Ozkahya M, Toz H, et al. Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clin Transplant 2002; 16: 257-261. (Pubitemid 34830842)
20. Bennett DE, Courval JM, Onorato I, Agerton T, Gibson JD, Lambert L, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey. Am J Respir Crit Care Med 2008; 177: 348-355. (Pubitemid 351198380)
21. Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM., Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. HEPATOLOGY 2009; 50: 400-406.
22. Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M., Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007; 30: 945-950. (Pubitemid 351194799)
23. Piana F, Ruffo Codecasa L, Baldan R, Miotto P, Ferrarese M, Cirillo DM., Use of t-SPOT.TB in latent tuberculosis infection diagnosis in general and immunosuppressed populations. New Microbiol 2007; 30: 286-290. (Pubitemid 47264891)
24. Huebner RE, Schein MF, Bass JB., The tuberculin skin test. Clin Infect Dis 1993; 17: 968-975. (Pubitemid 23358739)
25. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, Mendiratta DK, et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005; 293: 2746-2755. (Pubitemid 40973379)
26. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631-635. (Pubitemid 41232976)
27. Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009; 48: 954-962.
28. Rubin RH., Management of tuberculosis in the transplant recipient. Am J Transplant 2005; 5: 2599-2600.
29. Torre-Cisneros J, de la Mata M, Rufian S, Villanueva Marcos JL, Gutierrez Aroca J, Casal M, et al. Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 1995; 60: 1054-1055.
30. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J., Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Saf 1996; 15: 394-405.
31. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161(4 pt 2): S221-S247.
32. Taylor Z, Nolan CM, Blumberg HM., Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005; 54: 1-81.
33. Salizzoni JL, Tiruviluamala P, Reichman LB., Liver transplantation: an unheralded probable risk for tuberculosis. Tuber Lung Dis 1992; 73: 232-238.
34. Jahng AW, Tran T, Bui L, Joyner JL., Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007; 83: 1557-1562. (Pubitemid 46987906)
35. Singh N, Wagener MM, Gayowski T., Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74: 892-895.
36. Bailey WC, Taylor SL, Dascomb HE, Greenberg HB, Ziskind MM., Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis 1973; 107: 523-529.
37. Byrd RB, Horn BR, Solomon DA, Griggs GA., Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 1979; 241: 1239-1241. (Pubitemid 9222048)
38. Nolan CM, Goldberg SV, Buskin SE., Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018. (Pubitemid 29143893)
39. Kopanoff DE, Snider DE Jr, Caras GJ., Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001. (Pubitemid 8380195)
40. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954. (Pubitemid 35440240)
41. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P., Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-1023. (Pubitemid 39232756)
42. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, Berk PD., Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63: 364-369. (Pubitemid 26343217)
43. Chaparro SV, Montoya JG, Keeffe EB, Rhee JT, Small PM., Risk of tuberculosis in tuberculin skin test-positive liver transplant patients. Clin Infect Dis 1999; 29: 207-208. (Pubitemid 29336829)